Skip to main content

Table 2 Relative risk (HRs and 95% Confidence Intervals, CI) of breast cancer death in association with dispensed ASA dose at different time periods following breast cancer diagnosis using a nested case–control design

From: Aspirin intake and breast cancer survival – a nation-wide study using prospectively recorded data in Sweden

Period

ASA dose

Cases

Controls

Model 1

Model 2

    

HR (95% CI)

HR (95% CI)

A

- Baseline (3 to 9 months after diagnosis)

  

(n = 1521)

(n = 3042)

  
 

0

1235 (81.2)

2481 (81.6)

1.00

1.00

<1 daily dose

78 (5.1)

146 (4.8)

1.08 (0.81; 1.44)

1.13 (0.84; 1.52)

≥ 1 daily dose

208 (13.7)

415 (13.6)

1.01 (0.84; 1.23)

0.97 (0.79; 1.18)

B

- 12 to 6 months before end of follow-up

  

(n = 1211)

(n = 2422)

  
 

0

964 (79.6)

1961 (81.0)

1.00

1.00

<1 daily dose

72 (5.9)

138 (5.7)

1.08 (0.80; 1.46)

1.05 (0.77; 1.44)

≥ 1 daily dose

175 (14.5)

323 (13.3)

1.12 (0.90; 1.38)

1.02 (0.81; 1.28)

C

- 9 to 3 months before end of follow-up

  

(n = 1380)

(n = 2760)

  
 

0

1102 (79.9)

2216 (80.3)

1.00

1.00

<1 daily dose

81 (5.9)

152 (5.5)

1.07 (0.81; 1.42)

1.00 (0.74; 1.34)

≥ 1 daily dose

197 (14.3)

392 (14.2)

1.01 (0.83; 1.24)

0.93 (0.75; 1.15)

D

- 6 to 0 months before end of follow-up

  

(n = 1521)

(n = 3042)

  
 

0

1220 (80.2)

2420 (79.6)

1.00

1.00

<1 daily dose

120 (7.9)

159 (5.2)

1.49 (1.16; 1.92)

1.43 (1.09; 1.87)

≥ 1 daily dose

181 (11.9)

463 (15.2)

0.77 (0.63; 0.93)

0.69 (0.56; 0.86)

  1. Model 1: Logistic regression model with adjustment for the matching factors age at diagnosis, calendar year of diagnosis, and time since diagnosis.
  2. Model 2: Additional adjustment for comorbidity (in groups of disorders associated with increased or decreased use of ASA) and highest obtained educational level (≤9 years, 10–12 years, >12 years).